Minority Health/Disparities: Study confirms underuse of lipid-lowering agents by Medicaid-insured minority patients with cardiovascular disease

2005 ◽  
Author(s):  
Jacek Rysz ◽  
Beata Franczyk ◽  
Robert Olszewski ◽  
Maciej Banach ◽  
Anna Gluba-Brzozka

2021 ◽  
pp. 475-483
Author(s):  
Keith C. Norris ◽  
Bettina M. Beech ◽  
David Heber

2005 ◽  
Vol 19 (6_suppl) ◽  
pp. 66-75 ◽  
Author(s):  
Ian S. Young

Serum cholesterol is a major risk factor for cardiovascular disease. Total cholesterol, LDL cholesterol and triglycerides are positively related to cardiovascular disease, while HDL cholesterol has an inverse relationship. Measurement of lipids is essential in individuals with established cardiovascular disease or type 2 diabetes, and may also be carried out in healthy individuals as part of cardiovascular risk assessment. Lifestyle measures are important in cardiovascular disease prevention, but the mainstay of lipid lowering therapy is appropriate use of lipid lowering drugs. Total and LDL cholesterol are the primary targets for treatment, but consideration should also be given to raising HDL cholesterol and lowering triglycerides where appropriate. Statins are the most frequently used lipid lowering agents, but there is an important place for other drugs, including ezetimibe, fibrates and nicotinic acid.


Sign in / Sign up

Export Citation Format

Share Document